← All trials
NCT06952478
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 12, 2025
- Primary completion
- Nov 15, 2027
- Completion date
- Jun 25, 2029
- First posted
- May 1, 2025
- Last posted
- Aug 15, 2025
- Enrollment
- 486
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- CelltrionLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.